Breast Cancer

Raloxifene, exemestane may provide postmenopausal breast cancer risk reduction

Published in Women's Health Weekly, July 8th, 2004

Attendees at the 40th annual meeting of the Association of Clinical Oncologists were updated on the serum estrogen receptor modulator (SERM) raloxifene and the aromatase inhibitor (AI) exemestane, with newest research findings presented on the possible benefits they may provide for postmenopausal breast cancer risk reduction.

SERMs are a class of drugs that can block the cell's ability to use estrogen to stimulate the development of breast cancer. This class of anti-estrogens includes tamoxifen, which is currently used by thousands of postmenopausal women with estrogen-receptor positive cancer to prevent recurrence following completion of their chemotherapy.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-07-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry